Allergan

Quick facts

Marketed products

• Botox · Neuroscience · revenue 5300
  BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25.
• 0.15% Brimonidine Tartrate
• ACZONE Gel, 5% · Dermatology
  Dapsone reduces inflammation and bacterial colonization in acne lesions through its antimicrobial and anti-inflammatory properties.
• AGN-190584 · Other
• Alcaftadine 0.25%
• alcaftadine 0.25% ophthalmic solution · Ophthalmology
  Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.
• Androderm® · Endocrinology
  Androderm delivers testosterone transdermally to replace deficient testosterone in hypogonadal men.
• BELKYRA®
• Bimatoprost 0.01% · Ophthalmology
  Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
• bimatoprost 0.01% ophthalmic solution
• bimatoprost 0.03% eye drops
• bimatoprost 0.03% ophthalmic solution · Ophthalmology
  Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
• bimatoprost 0.03% plus timolol 0.5%
• Bimatoprost Ophthalmic Solution · Ophthalmology
  Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
• Bimatoprost Ophthalmic Solution 0.01%
• bimatoprost ophthalmic solution 0.03%
• Bimatoprost Vehicle · Ophthalmology
  Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
• Botulinum Toxin Type A 150kDa
• Botulinum Toxin Type A 900kD · Neurology; Aesthetics; Ophthalmology
  Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
• Botulinum Toxin Type A 900kDa · Neurology; Aesthetics; Ophthalmology
  Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
• brimonidine 0.1% (Alphagan® P) · Ophthalmology
  Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow in the eye.
• Brimonidine 0.2% ophthalmic solution
• Brimonidine ophthalmic solution 0.1% · Ophthalmology
  Brimonidine is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
• brimonidine tartrate ophthalmic solution · Ophthalmology
  Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
• carboxymethylcellulose 0.5% +glycerin 0.9% · Ophthalmology
  Carboxymethylcellulose and glycerin work together to lubricate and hydrate the ocular surface, providing relief from dry eye symptoms.
• carboxymethylcellulose-based lubricant eye drops · Ophthalmology
  Carboxymethylcellulose acts as a viscous lubricant that coats and protects the ocular surface, mimicking natural tears to relieve dryness and irritation.
• Carboxymethylcellulose sodium and Glycerin
• Clindamycin/benzoyl peroxide plus Adapalene · Dermatology
  This triple-combination topical treatment reduces acne through bacterial suppression (clindamycin), oxidative killing (benzoyl peroxide), and normalized skin cell turnover (adapalene).
• cyclosporine 0.05% ophthalmic emulsion
• Dapsone plus Adapalene · Dermatology
  Dapsone reduces inflammation and bacterial growth while adapalene normalizes skin cell turnover and reduces sebum production, together targeting acne pathogenesis.
• Dapsone; Tretinoin · Dermatology
  This combination of dapsone (an antimicrobial and anti-inflammatory agent) and tretinoin (a retinoid that promotes skin cell turnover) works synergistically to reduce inflammation and normalize skin cell differentiation in acne and rosacea.
• Dexamethasone intravitreal implant
• GoodSense Eye Drops Advanced Relief Moisturizer · Ophthalmology
• gatifloxacin ophthalmic solution 0.3% · Ophthalmology / Infectious Disease
  Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
• hypromellose 0.3% · Ophthalmology
  Hypromellose is a cellulose-based polymer that forms a protective lubricating film on the ocular surface to relieve dry eye symptoms.
• IV Placebo (Saline)
  IV saline placebo has no active pharmacological mechanism; it is a control comparator consisting of sterile sodium chloride solution.
• latanoprost 0.005%
• latanoprost 0.005% eye drops
• Lubricant Eye Drops (Optive™) · Ophthalmology
  Optive lubricates and protects the ocular surface by providing a multi-component tear substitute that mimics natural tears.
• Lubricating Eye Drop · Ophthalmology
  Lubricating eye drops provide artificial tears that coat and moisturize the ocular surface to relieve dryness and irritation.

Phase 3 pipeline

• Active Comparator: Timolol 0.5% · Ophthalmology
  Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
• AGN-199201 · Endocrinology / Musculoskeletal
  AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.
• AGN-229666 · Ophthalmology / Dermatology
  AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and promote tissue repair.
• Bimatoprost 0.03% sterile solution · Ophthalmology
  Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
• bimatoprost formulation A solution · Ophthalmology
  Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and reduced intraocular pressure.
• bimatoprost solution 0.03 % · Ophthalmology
  Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
• bimatoprost/timolol fixed combination
• Botox placebo (normal saline)
  Normal saline is an inert placebo with no active pharmacological mechanism.
• botulinum toxin Type A (12 U)
  Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
• botulinum toxin Type A (24 U) · Neurology
  Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
• botulinum toxin Type A (300U)
  Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
• botulinum toxin Type A (32U) · Neurology
  Botulinum toxin Type A (32U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
• botulinum toxin Type A (44U) · Neurology
  Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
• brimonidine/timolol fixed combination
• carboxymethylcellulose based eye drop formula · Ophthalmology
  Carboxymethylcellulose based eye drops act as artificial tears to lubricate and moisten the eye, providing relief from dryness and irritation.
• carboxymethylcellulose sodium based Eye Drops · Ophthalmology
  Carboxymethylcellulose sodium eye drops work by forming a protective barrier on the surface of the eye to help soothe and lubricate dry eyes.
• Cyclosporine 0.010% · Ophthalmology
  Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.
• Cyclosporine Vehicle · Ophthalmology / Immunology
  Cyclosporine is an immunosuppressant that inhibits T-cell activation by blocking calcineurin, thereby reducing inflammatory responses in the eye.
• Dapsone Topical Gel + adapalene gel 0.1% · Dermatology
  Dapsone provides antimicrobial and anti-inflammatory effects while adapalene is a retinoid that normalizes skin cell differentiation and reduces inflammation.
• Dapsone Topical Gel + vehicle control · Dermatology
  Dapsone is a sulfone antimicrobial and anti-inflammatory agent that inhibits bacterial folate synthesis and suppresses neutrophil function to reduce inflammation in acne.
• Gatifloxacin 0.5% eye drops · Ophthalmology / Infectious Disease
  Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
• ketorolac eye drops · Ophthalmology
  Ketorolac eye drops work by reducing inflammation and pain in the eye by inhibiting prostaglandin synthesis.
• MAP0004 · Oncology
  MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells.
• onabotulinumtoxinA 24 U
  onabotulinumtoxinA 24 U works by temporarily paralyzing muscles to treat muscle spasms and other conditions.
• onabotulinumtoxinA 44 U · Neurology
  onabotulinumtoxinA 44 U works by temporarily paralyzing muscles to treat various conditions.
• Pilocarpine HCl · Ophthalmology / Otolaryngology
  Pilocarpine HCl is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase salivary and lacrimal gland secretion.
• Placebo-matching Ubrogepant · Neurology
  Ubrogepant is a calcitonin gene-related peptide receptor antagonist.
• Systane Ultra Multidose · Ophthalmology
  Systane Ultra Multidose lubricates the eyes to help relieve dryness and irritation.
• Ulipristal acetate (UPA) · Women's health
  Ulipristal acetate acts as a selective progesterone receptor modulator (SPRM) to prevent ovulation and thicken cervical mucus, thereby inhibiting sperm penetration.
• vehicle of bimatoprost solution 0.03 % · Ophthalmology
  Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and decreased intraocular pressure.
• Vehicle Ophthalmic Solution · Ophthalmology
  Vehicle ophthalmic solution is a clear liquid used to lubricate the eyes.
• Vehicle to AGN-199201 · Pain Management / Neurology
  AGN-199201 is a selective antagonist of the neurokinin-1 (NK1) receptor that modulates pain signaling in the central nervous system.
• Vehicle to AGN-229666 · Dermatology or Ophthalmology
  AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair.
• Vehicle to bimatoprost solution · Ophthalmology
  Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
• Vehicle to Oxymetazoline HCL Cream · Dermatology
  Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema.

Phase 2 pipeline

• AGN-150998
• AGN-190584 ophthalmic solution · Ophthalmology
  AGN-190584 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.
• AGN-195263 0.01%
• AGN-195263 0.03% · Diabetes
  AGN-195263 is a glucagon receptor antagonist.
• AGN-195263 0.1% · Ophthalmology
  AGN-195263 is a topical ophthalmic agent that modulates intraocular pressure through enhanced aqueous humor outflow.
• AGN-199201 Dose A · Musculoskeletal / Endocrinology
  AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.
• AGN-199201 Dose B
  AGN-199201 Dose B is a drug that targets the molecular target to exert its therapeutic effect.
• AGN-199201 Dose C
  AGN-199201 Dose C is a drug that targets the molecular target to exert its therapeutic effect.
• AGN-199201 ophthalmic solution · Ophthalmology
  AGN-199201 is a selective prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
• AGN-210669 · Pain Management
  AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons.
• AGN-210669 ophthalmic solution, 0.05% · Ophthalmology
  AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.
• AGN-210669 ophthalmic solution, 0.075%
• AGN-210669 ophthalmic solution, 0.1% · Ophthalmology
  AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.
• AGN-210961 Formulation 1 · Diabetes
  AGN-210961 is a small molecule targeting the SGLT2 receptor.
• AGN-210961 Formulation 2
• AGN-210961 Formulation 3
• AGN-210961 Formulation 4
• AGN-210961 Formulation 5 · Cardiovascular
  AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol.
• AGN-210961 Formulation 6 · Endocrinology / Musculoskeletal
  AGN-210961 is a selective androgen receptor modulator (SARM) designed to provide tissue-selective androgenic effects.
• AGN-210961 Formulation 7 · Cardiovascular
  AGN-210961 Formulation 7 is a drug that targets the PCSK9 protein to lower LDL cholesterol.
• AGN-223575 ophthalmic solution · Ophthalmology
  AGN-223575 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.
• Alcaftadine Ophthalmic Solution 0.25% · Ophthalmology
  Antihistamine
• Any Fixed Combination Therapy
  This fixed combination therapy works by combining multiple drugs to treat various conditions.
• Artificial Tears REFRESH ENDURA® · Ophthalmology
  REFRESH ENDURA artificial tears lubricate and protect the eyes by forming a thin layer on the surface of the eye.
• Bimatoprost 0.02% ophthalmic solution
• Bimatoprost cutaneous solution 0.03% · Ophthalmology
  Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure.
• bimatoprost eye drops
• bimatoprost Formulation B
• bimatoprost Formulation C
• bimatoprost ophthalmic solution 0.005%
• bimatoprost ophthalmic solution 0.015%
• Bimatoprost Solution 1
• Bimatoprost Solution 2 · Ophthalmology
  Prostaglandin F2α analogue
• BOTOX® purified neurotoxin complex · Neurology
  Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction.
• botulinum toxin type A Formulation 2
• Brimo PS DDS® · Urology
  Brimo PS DDS is a testosterone replacement therapy.
• Ciprofloxacin 0.3% ophthalmic solution · Ophthalmology
  Ciprofloxacin 0.3% ophthalmic solution works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and transcription.
• Cyclosporine 0.005% eye drops
• Cyclosporine 0.010% eye drops · Immunology
  Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.
• DEX PS DDS® · Dermatology
  DEX PS DDS is a corticosteroid used to reduce inflammation and suppress the immune system.

Phase 1 pipeline

• AGN-190168 Formulation 1
• AGN-190168 Formulation 2
• AGN-199201 Formulation A
• AGN-199201 Formulation B
• AGN-199201 Formulation C
• AGN-210669 ophthalmic solution, 0.025%
• AGN-223575 Formulation A
• AGN-223575 Formulation B
• AGN-223575 Formulation C
• AGN-232411
• AGN208397 intravitreal injection
• AGN211745
• Bimatoprost 1% Formulation A
• Bimatoprost 1% Formulation B
• bimatoprost 10 µg generation 2
• bimatoprost 15 µg generation 1
• bimatoprost 15 µg generation 2
• bimatoprost 20 µg generation 2
• bimatoprost 6 µg generation 2
• cyclosporine ophthalmic emulsion Formulation A
• cyclosporine ophthalmic emulsion Formulation B
• IV DHE
• LiRIS low dose and LiRIS high dose
• MAP0010 intermediate dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Allergan portfolio CI brief
• Allergan pipeline updates RSS